[go: up one dir, main page]

PL1976521T3 - Spray fentanylu do podawania podjęzykowego - Google Patents

Spray fentanylu do podawania podjęzykowego

Info

Publication number
PL1976521T3
PL1976521T3 PL07762549T PL07762549T PL1976521T3 PL 1976521 T3 PL1976521 T3 PL 1976521T3 PL 07762549 T PL07762549 T PL 07762549T PL 07762549 T PL07762549 T PL 07762549T PL 1976521 T3 PL1976521 T3 PL 1976521T3
Authority
PL
Poland
Prior art keywords
sublingual fentanyl
fentanyl spray
spray
sublingual
fentanyl
Prior art date
Application number
PL07762549T
Other languages
English (en)
Inventor
S George Kottayil
Venkat R Goskonda
Zhongyuan Zhu
Linet Kattookaran
Neha N Parikh
Original Assignee
Insys Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38309867&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1976521(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Insys Therapeutics Inc filed Critical Insys Therapeutics Inc
Publication of PL1976521T3 publication Critical patent/PL1976521T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL07762549T 2006-01-25 2007-01-25 Spray fentanylu do podawania podjęzykowego PL1976521T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US76205706P 2006-01-25 2006-01-25
PCT/US2007/002163 WO2007087431A2 (en) 2006-01-25 2007-01-25 Sublingual fentanyl spray
EP07762549.9A EP1976521B1 (en) 2006-01-25 2007-01-25 Sublingual fentanyl spray

Publications (1)

Publication Number Publication Date
PL1976521T3 true PL1976521T3 (pl) 2015-10-30

Family

ID=38309867

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07762549T PL1976521T3 (pl) 2006-01-25 2007-01-25 Spray fentanylu do podawania podjęzykowego

Country Status (16)

Country Link
US (6) US8486972B2 (pl)
EP (2) EP1976521B1 (pl)
JP (3) JP5241514B2 (pl)
CN (1) CN101378735B (pl)
AU (1) AU2007208229B2 (pl)
BR (1) BRPI0707235B8 (pl)
CA (1) CA2637672C (pl)
DK (1) DK1976521T3 (pl)
ES (1) ES2535233T3 (pl)
MX (3) MX2008009522A (pl)
NZ (1) NZ569949A (pl)
PL (1) PL1976521T3 (pl)
PT (1) PT1976521E (pl)
RU (1) RU2432950C2 (pl)
SI (1) SI1976521T1 (pl)
WO (1) WO2007087431A2 (pl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001281746C1 (en) * 2000-07-31 2010-09-09 ISTITUTO GENTILI S.r.l. Fentanyl composition for nasal administration
JP5241514B2 (ja) 2006-01-25 2013-07-17 インシス セラピューティクス インコーポレイテッド 舌下フェンタニルスプレー
US8210167B2 (en) * 2007-03-02 2012-07-03 Corbco, Inc. Manually operated monodose nasal sprayer
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
PL2180844T3 (pl) 2007-08-02 2018-07-31 Insys Development Company, Inc. Rozpylacz podjęzykowy z fentanylem
GB0720967D0 (en) * 2007-10-25 2007-12-05 Protophama Ltd Anti-material pharmaceutical composition
JP5789100B2 (ja) * 2008-01-22 2015-10-07 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 抽出溶媒を含む、局部的な麻酔および／または疼痛低減のための揮発性麻酔薬組成物
US20090286832A1 (en) * 2008-05-15 2009-11-19 Kiichiro Nabeta Narcotic emulsion formulations for treatment of surgical pain
JP5619780B2 (ja) 2009-02-26 2014-11-05 テイコク ファーマ ユーエスエー インコーポレーテッド 癌性疼痛の治療のための麻薬性エマルション製剤
GB2469792A (en) * 2009-04-23 2010-11-03 Calvin John Ross Oil-based pharmaceutical formulation for sublingual delivery
CA2756879A1 (en) * 2009-04-23 2010-10-28 Londonpharma Ltd. Sublingual pharmaceutical composition comprising a neutral oil
NZ596976A (en) * 2009-05-15 2014-05-30 Recro Pharma Inc Sublingual dexmedetomidine compositions and methods of use thereof
WO2011028629A1 (en) * 2009-08-26 2011-03-10 Nuvo Research Inc. Pharmaceutical formulations and methods of use
BR112012012315A2 (pt) * 2009-11-23 2018-10-16 Cipla Ltd composição farmacêutica para administração retal tópica na forma de espuma, uso de uma composição farmacêutica, método para tratamento, prevenção ou alívio de um dustúrbio no reto, cólon, íleo terminal ou anus, processo para fabricação de uma composição farmacêutica contendo rifaximina, uso de silicone e dispensador para composição farmacêutica
US20120295893A1 (en) * 2009-12-14 2012-11-22 Coeruleus Ltd. Compositions and methods of counteracting residual sedative effects of sleep/ hypnotic drugs
GB2483579A (en) * 2010-06-30 2012-03-14 Londonpharma Ltd Sublingual formulations comprising methadone and ethanol for use in reducing pain
US8627816B2 (en) 2011-02-28 2014-01-14 Intelliject, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
US8939943B2 (en) 2011-01-26 2015-01-27 Kaleo, Inc. Medicament delivery device for administration of opioid antagonists including formulations for naloxone
GB2487007B (en) * 2012-03-19 2013-06-05 Londonpharma Ltd COC containers and delivery devices for the sublingual administration of opioids
US9867818B2 (en) 2013-09-10 2018-01-16 Insys Development Company, Inc. Sublingual buprenorphine spray
US9918981B2 (en) 2013-09-10 2018-03-20 Insys Development Company, Inc. Liquid buprenorphine formulations
US9839611B2 (en) 2013-09-10 2017-12-12 Insys Development Company, Inc. Sublingual buprenorphine spray
US9216175B2 (en) 2013-09-10 2015-12-22 Insys Pharma, Inc. Sublingual buprenorphine spray
US9956166B2 (en) 2013-09-18 2018-05-01 Sorrento Therapeutics, Inc. Methods for administration and methods for treating cardiovascular diseases with resiniferatoxin
JP2016540748A (ja) * 2013-11-14 2016-12-28 インシス・ファーマ・インコーポレーテッド オンダンセトロン舌下スプレー製剤
US11135155B2 (en) 2014-07-08 2021-10-05 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10617686B2 (en) * 2014-07-08 2020-04-14 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US10722510B2 (en) * 2014-07-08 2020-07-28 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US9642848B2 (en) * 2014-07-08 2017-05-09 Insys Development Company, Inc. Sublingual naloxone spray
US10441538B2 (en) * 2014-07-08 2019-10-15 Hikma Pharmaceuticals Usa Inc. Liquid naloxone spray
US20160199294A1 (en) * 2014-07-08 2016-07-14 Insys Development Company, Inc. Sublingual naloxone spray
US9855234B2 (en) * 2014-07-08 2018-01-02 Insys Development Company, Inc. Diclofenac sublingual spray
US9517307B2 (en) 2014-07-18 2016-12-13 Kaleo, Inc. Devices and methods for delivering opioid antagonists including formulations for naloxone
US10172833B2 (en) 2015-08-11 2019-01-08 Insys Development Company, Inc. Sublingual ondansetron spray
KR102508022B1 (ko) * 2016-04-13 2023-03-10 보드 오브 리젠츠 오브 디 유니버시티 오브 네브라스카 레시니페라톡신을 사용한 투여 방법 및 심혈관 질환을 치료하는 방법
WO2017205710A1 (en) * 2016-05-27 2017-11-30 Insys Development Company, Inc. Sublingual fentanyl formulations containing a permeation enhancer
US9650338B1 (en) 2016-07-29 2017-05-16 VDM Biochemicals, Inc. Opioid antagonist compounds and methods of making and using
AU2021217164A1 (en) * 2020-02-05 2022-08-25 Summit Biosciences Inc. Drug products for intranasal administration and uses thereof
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4244478A (en) 1979-06-27 1981-01-13 Mpl, Inc. Closure assembly for unit dose vial
GB8900267D0 (en) 1989-01-06 1989-03-08 Riker Laboratories Inc Narcotic analgesic formulations and apparatus containing same
US5219083A (en) 1992-04-02 1993-06-15 Sterling Winthrop Inc. Stopper for reduction of particulate matter
US5976504A (en) 1993-08-10 1999-11-02 The Boots Company, Plc Topical aerosol formulation for cooling of mammalian tissues
ATE223202T1 (de) 1994-09-30 2002-09-15 Mika Pharma Ges Fuer Die Entwi Pharmazeutische zusammensetzung
US20030077229A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs
US20030095926A1 (en) 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the gastrointestinal tract or urinary tract
US20030095925A1 (en) 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
US20040136914A1 (en) 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing ondansetron
US20050163719A1 (en) 1997-10-01 2005-07-28 Dugger Harry A.Iii Buccal, polar and non-polar spray containing diazepam
US20040141923A1 (en) 1997-10-01 2004-07-22 Dugger Harry A. Buccal, polar and non-polar spray containing alprazolam
US20040136913A1 (en) 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing sumatriptan
US20030077228A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating endocrine disorders
US20050281752A1 (en) 1997-10-01 2005-12-22 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20040136915A1 (en) 1997-10-01 2004-07-15 Dugger Harry A. Buccal, polar and non-polar spray containing atropine
US20030077227A1 (en) 1997-10-01 2003-04-24 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating disorders of the central nervous system
US20050002867A1 (en) 1997-10-01 2005-01-06 Novadel Pharma Inc. Buccal, polar and non-polar sprays containing propofol
US20030095927A1 (en) 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating muscular and skeletal disorders
US20090162300A1 (en) 1997-10-01 2009-06-25 Dugger Iii Harry A Buccal, polar and non-polar spray containing alprazolam
US20050180923A1 (en) 1997-10-01 2005-08-18 Dugger Harry A.Iii Buccal, polar and non-polar spray containing testosterone
US20030190286A1 (en) 1997-10-01 2003-10-09 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
US20050287075A1 (en) 1997-10-01 2005-12-29 Dugger Harry A Iii Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US20030082107A1 (en) 1997-10-01 2003-05-01 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer
US20030185761A1 (en) 1997-10-01 2003-10-02 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating pain
US7632517B2 (en) 1997-10-01 2009-12-15 Novadel Pharma Inc. Buccal, polar and non-polar spray containing zolpidem
WO1999016417A1 (en) 1997-10-01 1999-04-08 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
SE9803239D0 (sv) 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
US7087215B2 (en) * 1998-12-21 2006-08-08 Generex Pharmaceuticals Incorporated Methods of administering and enhancing absorption of pharmaceutical agents
AU2879100A (en) 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
EP1296649A2 (en) * 2000-06-22 2003-04-02 Pharmasol Limited Pharmaceutical compositions comprising an opioid analgesic
WO2002045713A2 (en) 2000-12-04 2002-06-13 Sepracor, Inc. Orally-bioavailable formulations of fentanyl and congeners thereof
US20040092428A1 (en) 2001-11-27 2004-05-13 Hongming Chen Oral pharmaceuticals formulation comprising paclitaxel, derivatives and methods of administration thereof
US6946150B2 (en) 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
WO2004075877A1 (en) * 2003-02-24 2004-09-10 Pharmaceutical Productions, Inc. Transmucosal drug delivery system
US20060062812A1 (en) * 2003-03-11 2006-03-23 Calvin Ross Novel compositions
GB0305579D0 (en) * 2003-03-11 2003-04-16 Dallas Burston Ltd Pharmaceutical compositions
JP2006519770A (ja) * 2003-03-11 2006-08-31 アラキス リミテッド 新規組成物
GB0514043D0 (en) 2005-07-08 2005-08-17 Arakis Ltd Fentanyl formulation
US20070124554A1 (en) * 2005-10-28 2007-05-31 Honeywell International Inc. Global memory for a rapidio network
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
JP5241514B2 (ja) 2006-01-25 2013-07-17 インシス セラピューティクス インコーポレイテッド 舌下フェンタニルスプレー
PL2180844T3 (pl) 2007-08-02 2018-07-31 Insys Development Company, Inc. Rozpylacz podjęzykowy z fentanylem

Also Published As

Publication number Publication date
US20070261695A1 (en) 2007-11-15
RU2008130763A (ru) 2010-02-27
CN101378735B (zh) 2013-04-03
JP2013056928A (ja) 2013-03-28
EP2641595A1 (en) 2013-09-25
JP5241514B2 (ja) 2013-07-17
PT1976521E (pt) 2015-06-09
US8835460B2 (en) 2014-09-16
SI1976521T1 (sl) 2015-06-30
AU2007208229B2 (en) 2009-11-05
AU2007208229A1 (en) 2007-08-02
CA2637672C (en) 2012-07-24
US20160193142A1 (en) 2016-07-07
US10016403B2 (en) 2018-07-10
WO2007087431A3 (en) 2008-09-25
EP1976521B1 (en) 2015-03-11
DK1976521T3 (en) 2015-04-27
US9642797B2 (en) 2017-05-09
RU2432950C2 (ru) 2011-11-10
US8486972B2 (en) 2013-07-16
JP5630877B2 (ja) 2014-11-26
US20170202820A1 (en) 2017-07-20
BRPI0707235B1 (pt) 2020-04-14
US20130327321A1 (en) 2013-12-12
EP1976521A4 (en) 2010-11-03
NZ569949A (en) 2011-10-28
BRPI0707235A2 (pt) 2011-04-26
US9289387B2 (en) 2016-03-22
MX2020008616A (es) 2020-09-21
WO2007087431A2 (en) 2007-08-02
CA2637672A1 (en) 2007-08-02
JP2013127003A (ja) 2013-06-27
CN101378735A (zh) 2009-03-04
JP2009528272A (ja) 2009-08-06
US20140343100A1 (en) 2014-11-20
MX374396B (es) 2025-03-06
ES2535233T3 (es) 2015-05-06
US20180303813A1 (en) 2018-10-25
MX2008009522A (es) 2009-01-07
EP1976521A2 (en) 2008-10-08
BRPI0707235B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
SI1976521T1 (sl) Podjezično fentanilno pršilo
PL2180844T3 (pl) Rozpylacz podjęzykowy z fentanylem
IL195246A0 (en) Atomiser
DE602007008470D1 (en) Off
GB0613955D0 (en) Controller
ZA200810729B (en) Spray device
EG25598A (en) Casting nozzle
GB0716905D0 (en) Nozzle
GB0616226D0 (en) Processes
GB0625687D0 (en) Spray device
EP1983874A4 (en) BUSE
GB0620727D0 (en) Spray masks
GB201000798D0 (en) Poly-TLR antagonists
GB0609434D0 (en) Spray nozzle
GB2443193B (en) Railing
GB0617808D0 (en) Nozzle
GB2434853B (en) Spray device
GB0611418D0 (en) Improved spray head for ablutionary applicances
GB2443161B (en) Clobetasol spray
GB0607667D0 (en) Spray nozzle
GB0621406D0 (en) Kirby
GB0605740D0 (en) Spray
AU309692S (en) Spray can
GB0605165D0 (en) Key spray
GB0622066D0 (en) Nozzle